Giovanni Occhipinti

At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent.

The post-hoc analysis found that quantitative flow ratio (QFR)-based deferral of coronary artery revascularisation resulted in a higher incidence of 1-year major adverse cardiac events (MACE) as compared with fractional flow reserve (FFR)-based deferral.

The rationale for this study was to provide direct evidence of colchicine's effects on plaque stabilization, particularly by assessing changes in plaque characteristics using optical coherence tomography (OCT).

This study demonstrated, for the first time, that PPG - an index to characterize focal vs. diffuse disease - can predict optimal functional revascularization outcomes (post-PCI FFR ≥ 0.88) more accurately than FFR alone.

The trial aimed to establish the non-inferiority of QCA-guided PCI compared to IVUS-guided PCI with respect to the primary endpoint of TLF at 12 months, defined as a composite of cardiac death, target vessel MI, or ischemia-driven target lesion revascularization.

This patient-level analysis of randomized trials comparing PCI vs CABG for the treatment of low-to-intermediate CAD involving the LM confirms the absence of long-term differences in mortality between revascularization techniques, regardless of the clinical presentation.

A transdermal-infrared spectrophotometric sensor (T-ISS) to assess troponins increase has been recently developed. This multicenter, observational study tested the feasibility of implementing this tool with machine learning analytics carried out in a cohort of patients presenting with acute coronary syndrome.